Opko Health Inc. (NASDAQ:OPK) was the recipient of a significant decrease in short interest in November. As of November 30th, there was short interest totalling 61,166,624 shares, a decrease of 3.1% from the November 15th total of 63,133,301 shares. Based on an average daily volume of 4,822,048 shares, the days-to-cover ratio is presently 12.7 days. Approximately 18.5% of the company’s stock are sold short.

OPK has been the subject of several research analyst reports. BidaskClub downgraded Opko Health from a “hold” rating to a “sell” rating in a report on Saturday, November 11th. Cantor Fitzgerald initiated coverage on Opko Health in a report on Thursday, August 17th. They issued an “overweight” rating and a $20.00 price objective for the company. Ladenburg Thalmann Financial Services reissued a “buy” rating and issued a $16.00 price objective on shares of Opko Health in a report on Monday, September 25th. Zacks Investment Research downgraded Opko Health from a “hold” rating to a “sell” rating in a report on Tuesday, November 14th. Finally, J P Morgan Chase & Co downgraded Opko Health from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $12.00 to $7.00 in a report on Thursday, September 14th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $13.97.

Shares of Opko Health (OPK) opened at $5.13 on Thursday. Opko Health has a 52 week low of $4.50 and a 52 week high of $12.15. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.48 and a current ratio of 1.66.

Opko Health (NASDAQ:OPK) last released its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.08) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.03). Opko Health had a negative return on equity of 5.17% and a negative net margin of 9.45%. The company had revenue of $263.50 million for the quarter, compared to analysts’ expectations of $319.43 million. During the same quarter last year, the company earned ($0.03) EPS. Opko Health’s revenue for the quarter was down 11.6% compared to the same quarter last year. sell-side analysts anticipate that Opko Health will post -0.27 earnings per share for the current fiscal year.

In other Opko Health news, major shareholder Opko Health, Inc. purchased 655,738 shares of the stock in a transaction that occurred on Monday, October 30th. The stock was purchased at an average cost of $3.05 per share, with a total value of $2,000,000.90. Following the completion of the acquisition, the insider now directly owns 6,678,752 shares of the company’s stock, valued at approximately $20,370,193.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Phillip Md Et Al Frost purchased 80,000 shares of the stock in a transaction that occurred on Friday, September 15th. The stock was acquired at an average cost of $6.01 per share, with a total value of $480,800.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at $18,444,395.51. The disclosure for this purchase can be found here. Insiders purchased 792,238 shares of company stock valued at $2,819,996 over the last ninety days. 40.19% of the stock is currently owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the company. State Board of Administration of Florida Retirement System raised its stake in shares of Opko Health by 7.5% during the second quarter. State Board of Administration of Florida Retirement System now owns 400,278 shares of the biotechnology company’s stock worth $2,634,000 after purchasing an additional 27,940 shares during the last quarter. Intrinsic Edge Capital Management LLC purchased a new stake in shares of Opko Health during the second quarter worth approximately $658,000. Alps Advisors Inc. raised its stake in shares of Opko Health by 9.1% during the third quarter. Alps Advisors Inc. now owns 550,909 shares of the biotechnology company’s stock worth $3,779,000 after purchasing an additional 45,985 shares during the last quarter. Balyasny Asset Management LLC raised its stake in shares of Opko Health by 78.7% during the second quarter. Balyasny Asset Management LLC now owns 40,262 shares of the biotechnology company’s stock worth $265,000 after purchasing an additional 17,728 shares during the last quarter. Finally, ETF Managers Group LLC purchased a new stake in shares of Opko Health during the second quarter worth approximately $702,000. Institutional investors and hedge funds own 22.91% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was originally published by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/12/14/opko-health-inc-opk-short-interest-down-3-1-in-november.html.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.